Pacific Biosciences of California, Inc. (PACB) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 9 Buy, 8 Hold, 1 Sell.
The consensus price target is $2.74 (low: $1.50, high: $4.00), representing an upside of 74.6% from the current price $1.57.
Analysts estimate Earnings Per Share (EPS) of $-1.35 and revenue of $0.16B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.13 vs est $-1.35 (beat +16.5%). 2025: actual $-1.82 vs est $-1.85 (beat +1.5%). Analyst accuracy: 89%.
PACB Stock — 12-Month Price Forecast
$2.74
▲ +74.63% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Pacific Biosciences of California, Inc., the average price target is $2.74, with a high forecast of $4.00, and a low forecast of $1.50.
The average price target represents a +74.63% change from the last price of $1.57.
Highest Price Target
$4.00
Average Price Target
$2.74
Lowest Price Target
$1.50
PACB Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Pacific Biosciences of California, Inc. in the past 3 months
EPS Estimates — PACB
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.13
vs Est –$1.35
▲ 19.8% off
2025
Actual –$1.82
vs Est –$1.85
▲ 1.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — PACB
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.154B
vs Est $0.155B
▼ 0.6% off
2025
Actual $0.160B
vs Est $0.158B
▲ 1.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
